ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 185 filers reported holding ASCENDIS PHARMA A/S in Q3 2022. The put-call ratio across all filers is 0.09 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $552,289 | +48.2% | 5,898 | +41.3% | 0.26% | +50.6% |
| Q2 2023 | $372,619 | -52.6% | 4,175 | -43.1% | 0.17% | -73.5% |
| Q1 2023 | $786,780 | -12.2% | 7,338 | 0.0% | 0.64% | +20.5% |
| Q4 2022 | $896,190 | -11.3% | 7,338 | -25.0% | 0.53% | -7.8% |
| Q3 2022 | $1,010,000 | +46.0% | 9,780 | +31.4% | 0.58% | +38.0% |
| Q2 2022 | $692,000 | -24.6% | 7,442 | -4.8% | 0.42% | -28.4% |
| Q1 2022 | $918,000 | -20.1% | 7,821 | -8.4% | 0.58% | -36.2% |
| Q4 2021 | $1,149,000 | -26.2% | 8,541 | -12.6% | 0.92% | -11.2% |
| Q3 2021 | $1,557,000 | +95.4% | 9,769 | +61.2% | 1.03% | +82.3% |
| Q2 2021 | $797,000 | +12.4% | 6,060 | +10.1% | 0.56% | +7.2% |
| Q1 2021 | $709,000 | -10.1% | 5,505 | +16.4% | 0.53% | +4.6% |
| Q4 2020 | $789,000 | +54.7% | 4,731 | +43.1% | 0.50% | +35.5% |
| Q3 2020 | $510,000 | +19.2% | 3,307 | +14.3% | 0.37% | +5.1% |
| Q2 2020 | $428,000 | – | 2,893 | – | 0.35% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 2,003,147 | $225,574,000 | 20.44% |
| RA Capital Management | 4,914,955 | $553,473,000 | 17.48% |
| Sofinnova Investments, Inc. | 1,109,874 | $124,983,000 | 11.56% |
| Eversept Partners, LP | 275,494 | $31,023,379 | 7.71% |
| Avoro Capital Advisors LLC | 1,787,000 | $201,234,000 | 6.79% |
| Orbimed Advisors | 3,287,400 | $370,194,000 | 6.22% |
| Eventide Asset Management | 1,698,648 | $191,285,000 | 6.19% |
| Logos Global Management LP | 120,000 | $13,513,000 | 5.14% |
| Ghost Tree Capital, LLC | 150,000 | $16,892,000 | 4.48% |
| Spyglass Capital Management LLC | 351,388 | $39,570,000 | 4.47% |